Trevor Martin

In this engaging conversation, Trevor Martin, co-founder and CEO of Mammoth Biosciences, discusses groundbreaking CRISPR technologies and their capacity to rewrite our genetic code. He explores ethical dilemmas surrounding genetic modifications, emphasizing their potential to reshape human identity and health. From the implications for disease treatment to issues of access and equity, Trevor highlights how advancements in gene editing may influence our future. This thought-provoking dialogue encourages listeners to reflect on the societal impact of altering our biological legacy.

Trevor Martin, CEO of Mammoth Biosciences, and Ursheet Parikh, Partner at Mayfield Venture Capital, discuss building a platform biotech company, utilizing CRISPR technology for genetic diseases, choosing the right market, the importance of company infrastructure, the value of a PhD for entrepreneurs, and ethical considerations in biotech companies.

Trevor Martin, the CEO and co-founder of Mammoth Biosciences, shares insights on CRISPR technology, revolutionizing gene editing today rather than in a distant future. He discusses its potential to treat genetic diseases and the ethical implications of editing genes, especially concerning enhancing human capabilities. The conversation also dives into the accessibility challenges of biotechnology and the importance of societal consensus on genetic advancements, highlighting how these developments could reshape health outcomes and ethical boundaries in society.